(NASDAQ: RZLT) Rezolute's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Rezolute's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast RZLT's revenue for 2026 to be $187,659,818, with the lowest RZLT revenue forecast at $187,659,818, and the highest RZLT revenue forecast at $187,659,818. On average, 3 Wall Street analysts forecast RZLT's revenue for 2027 to be $1,441,953,824, with the lowest RZLT revenue forecast at $229,429,261, and the highest RZLT revenue forecast at $2,285,212,294.
In 2028, RZLT is forecast to generate $6,574,934,116 in revenue, with the lowest revenue forecast at $3,339,134,043 and the highest revenue forecast at $10,011,348,587.